Press Release: Hyperion Therapeutics : Hyperion Therapeutics, Inc. (HPTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - New Study Released

(PR-inside.com) Hyperion Therapeutics, Inc. (Hyperion) is a biopharmaceutical company. It develops and commercializes novel drugs for the treatment of orphan diseases and hepatology disorders. Ravicti, the company's first approved product is indicated for use as a nitrogen-binding agent in adult and pediatric patients aged above two years suffering with urea cycle disorders (UCDs) and those who cannot be treated by dietary protein restriction and amino acid supplementation alone. Ravicti (glycerol phenylbutyrate) lowers ammonia in the blood. The product is also being developed for a second orphan indication, hepatic encephalopathy (HE). Further, the company acquired another product candidate, Buphenyl (sodium phenylbutyrate) tablets ..